Results 101 to 110 of about 3,429 (181)

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer

eLife
Trastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies.
Yijia Hua, Ningjun Duan, Chunxiao Sun, Fan Yang, Min Tian, Yanting Sun, Shuhan Zhao, Jue Gong, Qian Liu, Xiang Huang, Yan Liang, Ziyi Fu, Wei Li, Yongmei Yin   +13 more
doaj   +1 more source

KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4

Cancer Science, EarlyView.
KYNU is upregulated in gastric cancer cells and activates the PI3K/Akt pathway, leading to PF4 secretion. PF4 drives nonclassical macrophage polarization with high expression of S100A8 and MMP7, which promotes tumor proliferation, migration, and invasion while suppressing phagocytosis, thereby accelerating gastric cancer progression.
Xilun Cui, Changfeng Li, Yuanda Liu, Chang Liu, Wei Yang   +4 more
wiley   +1 more source

TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776‐Altered Subtype of HER2‐Mutant NSCLC

Cancer Science, EarlyView.
A two‐stage clinicogenomic analysis identified and independently validated a preferential association between TERT promoter mutations and the ERBB2 G776‐altered subtype of HER2‐mutant NSCLC, highlighting subtype‐specific genomic heterogeneity. ABSTRACT HER2‐mutant non‐small cell lung cancer (NSCLC) comprises molecularly heterogeneous tumors with ...
Akihiro Yoshimura, Juichiro Yoshida, Chieko Takumi, Koichi Takayama   +3 more
wiley   +1 more source

S1 guideline sweat gland carcinoma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The current classification of sweat gland carcinomas is based on histomorphological characteristics and distinguishes between more than 20 entities. Most patients are older, but some subtypes also affect middle‐aged and younger patients. The majority of tumors arise de novo. Sweat gland carcinomas have nonspecific clinical features.
Mirjana Ziemer, Michael Erdmann, Abbas Agaimy, Jürgen C. Becker, Almut Böer‐Auer, Doris Helbig, Cornelia Erfurt‐Berge, Alexander Frisman, Conrad Hempel, Ulrike Leiter, Friedegund Meier, Thomas Mentzel, Lara Racz, Silke Redler, Stefan Schliep, Clemens Seidel, Alpaslan Tasdogan, Jochen Utikal, Carsten Weishaupt, Selma Ugurel   +19 more
wiley   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Postexercise muscle oxygen uptake kinetics in older breast cancer survivors and healthy individuals: Association with myosteatosis

Experimental Physiology, EarlyView.
Abstract Reduced cardiorespiratory fitness is common among breast cancer survivors and, although traditionally attributed to cardiac dysfunction, might also be related to peripheral skeletal muscle abnormalities. We examined peak and submaximal plantar‐flexion exercise and recovery kinetics for lower‐leg oxygen uptake (V̇O2${\dot V_{{{\mathrm{O}}_2}}}$)
Nathan R. Weeldreyer, Thomas J. McMurtry, Stephen J. Foulkes, Amanda Shewman, Edith Pituskin, Rachel J. Skow, Richard B. Thompson, Justin Grenier, Deirdre E. O'Neill, Robert C. Welsh, Mark J. Haykowsky, Corey R. Tomczak   +11 more
wiley   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 684-691, September 2026.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Improving Proteolysis‐Targeting Chimera Delivery by Targeting Key Biomarkers in Tumor Endocytosis Pathways

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
The image illustrates how PROTACs utilize endocytosis, mediated by cell surface proteins, to overcome bioavailability limitations and enable efficient intracellular delivery. ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are promising therapeutic agents for targeted protein degradation via the ubiquitin‐proteasome system; however, their clinical ...
Huahua Chen, Jiayan Jiao, Huiling Yang, Tao He   +3 more
wiley   +1 more source